Methioninase gene therapy for tumor treatment
    4.
    发明授权
    Methioninase gene therapy for tumor treatment 失效
    甲硫氨酸酶基因治疗肿瘤治疗

    公开(公告)号:US06524571B1

    公开(公告)日:2003-02-25

    申请号:US09195055

    申请日:1998-11-18

    申请人: Mingxu Xu Yuying Tan

    发明人: Mingxu Xu Yuying Tan

    IPC分类号: A01N4304

    摘要: A depletion method to inhibit tumor growth includes introducing a viral expression system capable of expressing methioninase or a fusion protein containing methioninase into a tumor contained in a vertebrate subject or cells thereof. The fusion protein may contain a fluorescent protein to permit monitoring of the completeness of the depletion method. The fusion protein can be used in vivo as well as in vitro screening protocols which employ the viral expression system. The expression system includes control sequences and means to integrate the nucleotide sequence into the genome of a host cell for expression. The method may also include treating the cells with isolated methioninase and/or with a therapeutic cell. The depletion method can be with other known therapies, such as maintaining the animal having the tumor on a methionine depleted diet.

    摘要翻译: 抑制肿瘤生长的消耗方法包括将能够表达蛋氨酸酶的病毒表达系统或含有蛋氨酸酶的融合蛋白引入到脊椎动物对象或其细胞中所含的肿瘤中。 融合蛋白可以含有荧光蛋白以允许监测耗尽方法的完整性。 融合蛋白可以在体内以及使用病毒表达系统的体外筛选方案中使用。 表达系统包括将核苷酸序列整合到宿主细胞的基因组中用于表达的控制序列和方法。 该方法还可以包括用分离的蛋氨酸酶和/或用治疗细胞处理细胞。 耗尽方法可以与其他已知的疗法一起使用,例如将具有肿瘤的动物维持在消耗蛋氨酸的饮食上。

    Methods for identifying markers for early-stage human cancer, cancer progression and recurrence
    5.
    发明授权
    Methods for identifying markers for early-stage human cancer, cancer progression and recurrence 失效
    识别早期人类癌症标志物,癌症进展和复发的方法

    公开(公告)号:US08217222B2

    公开(公告)日:2012-07-10

    申请号:US11529938

    申请日:2006-09-29

    CPC分类号: C12N15/1051 C12N15/1086

    摘要: A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression.

    摘要翻译: 描述了一种鉴定鉴定为癌症恶性程度的分泌蛋白的方法。 最初通过用含有可插入任何基因的含荧光蛋白的载体捕获蛋白质来鉴定蛋白质。 分泌的蛋白质最初通过其荧光来鉴定。 分离识别具有特定恶性程度的肿瘤的分泌蛋白,以确定它们是否可以作为癌症进展的标志物。

    Modulators of methylation for control of bacterial virulence
    7.
    发明授权
    Modulators of methylation for control of bacterial virulence 失效
    用于控制细菌毒力的甲基化调节剂

    公开(公告)号:US06632430B2

    公开(公告)日:2003-10-14

    申请号:US10334532

    申请日:2002-12-30

    IPC分类号: A61K3851

    摘要: Compositions and methods which ameliorate the virulence of bacterial infection are described wherein the active ingredient modulates transmethylation reactions in bacterial cells. Particularly useful compounds are inhibitors of S-adenosyl methionine synthetase (SAMS), of S-adenosyl homocysteine hydrolase (SAHH) and of transmethylases.

    摘要翻译: 描述了改善细菌感染的毒力的组合物和方法,其中活性成分调节细菌细胞中的转甲基化反应。 特别有用的化合物是S-腺苷甲硫氨酸合成酶(SAMS),S-腺苷同型半胱氨酸水解酶(SAHH)和转甲基酶的抑制剂。

    Biological fluid assay methods
    9.
    发明授权
    Biological fluid assay methods 有权
    生物流体测定方法

    公开(公告)号:US06329162B1

    公开(公告)日:2001-12-11

    申请号:US09550723

    申请日:2000-04-17

    IPC分类号: C12Q148

    CPC分类号: C12Q1/48 G01N2333/91011

    摘要: A method to assess the level of folate in a biological sample comprises: providing said sample with glycine N-methyltransferase (GMT) and with an excess of S-adenosyl methionine (SAM) and of glycine; providing a control which contains no folate with said GMT and excess SAM and glycine in comparable amounts to those provided to the sample; and comparing the concentration of at least one product formed in the sample with the concentrations of said product formed in the control, whereby the difference in levels of said product in the sample as compared to the control is directly proportional to the level of folate in the sample.

    摘要翻译: 评估生物样品中叶酸水平的方法包括:向所述样品提供甘氨酸N-甲基转移酶(GMT)和过量的S-腺苷甲硫氨酸(SAM)和甘氨酸;提供不含所述叶酸的叶酸的对照 GMT和过量的SAM和甘氨酸与提供给样品的量相当; 并将样品中形成的至少一种产品的浓度与对照中形成的所述产物的浓度进行比较,由此与对照相比,样品中所述产物的水平差异与样品中叶酸水平成正比 。

    High specificity homocysteine assays for biological samples
    10.
    发明授权
    High specificity homocysteine assays for biological samples 有权
    生物样品的高特异性同型半胱氨酸测定

    公开(公告)号:US6066467A

    公开(公告)日:2000-05-23

    申请号:US340991

    申请日:1999-06-28

    摘要: Novel enzymatic methods to determine the concentration of homocysteine in biological fluids are described. In a typical embodiment of the invention, the biological fluid sample is from a patient, and the methods of the invention are useful to assess risk for cardiovascular disease. The novel methods of the invention involve use of particular homocysteinase enzymes that permit the determination of homocysteine concentrations in biological samples without interference from the concentrations of cysteine and/or of methionine that are routinely present in such samples. There is also provided a diagnostic kit for use in determining the amount of homocysteine in a biological sample comprising (a) a homocysteinase having the aforementioned characteristics, and (b) at least one reagent capable of being used to determine the amount of product formed in the homocysteinase reaction. In a further aspect, the homocysteinase is provided as a chimeric molecule that comprises amino acid subsequences derived from, or patterned on, more than one homocysteinase, and which is typically produced from a chimeric polynucleotide that encodes therefor. Additional enhancements in homocysteine assay methodology include use of the enzyme .gamma.-glutamylcysteine synthetase to further limit any interference from cysteine present in the biological samples.

    摘要翻译: 描述了确定生物液体中同型半胱氨酸浓度的新型酶法。 在本发明的典型实施方案中,生物流体样品来自患者,本发明的方法可用于评估心血管疾病的风险。 本发明的新方法涉及使用特异性同型半胱氨酸酶,其允许在生物样品中测定同型半胱氨酸浓度,而不受这些样品中常规存在的半胱氨酸和/或甲硫氨酸的浓度的干扰。 还提供了用于确定生物样品中同型半胱氨酸量的诊断试剂盒,其包含(a)具有上述特征的同型半胱氨酸酶,和(b)至少一种能够用于测定形成的产物量的试剂 同型半胱氨酸酶反应。 在另一方面,提供同型半胱氨酸酶作为嵌合分子,其包含衍生自或多于一种同型半胱氨酸酶的图案化的氨基酸亚序列,并且其通常由其编码的嵌合多核苷酸产生。 同型半胱氨酸测定方法的其它改进包括使用γ-谷氨酰半胱氨酸合成酶来进一步限制存在于生物样品中的半胱氨酸的任何干扰。